Leerink analyst Faisal A. Khurshid initiated coverage of aTyr Pharma (ATYR) with an Outperform rating and $16 price target The firm has strong ...

Tyr Pharma, Inc. (NASDAQ:ATYR), a clinical-stage biotechnology company valued at $286.24 million, is garnering attention from investors and analysts alike as it advances its lead candidate, ...

The Roivant subsidiary Kinevant is to discontinue further development of namilumab for the treatment of sarcoidosis.

11 AP–HP, Hôpital Avicenne, Pulmonary Department and l'Université Paris 13, COMUE Sorbonne Paris Cité, EA 2363, Bobigny, France Background Sarcoidosis is a rare lung disease in children. The aim of ...

there is compelling evidence that those growing up with early life disadvantage are more likely to be diagnosed with occupational asthma and chronic obstructive pulmonary disease in adult life.8 In ...

A 61-year-old man with previously diagnosed pulmonary and nodal sarcoidosis presented with a 6-week history of right-upper-limb distal numbness. His neurological examination revealed depressed right ...

COPD is a progressive lung disease with mild symptoms in the early stages that gradually worsen. Early diagnosis and treatment can help preserve lung function. People with COPD often have trouble ...

(RTTNews) - aTyr Pharma, Inc. (ATYR), a clinical-stage biotechnology company, on Wednesday announced that it will present three important posters on efzofitimod at the American Thoracic Society or ...

The posters will cover the largest placebo-controlled trial in pulmonary sarcoidosis, real-world treatment patterns, and the incidence and mortality of the disease in the U.S. Efzofitimod ...

However, pulmonary manifestations and symmetric oligoarthritis ... the most likely autoimmune disorder in this case is sarcoidosis. This multisystem granulomatous disorder can involve any organ ...

He then compares plant and animal fat intake in overall cardiovascular disease outcomes. Finally, Dr. Eagle discusses a clinical consensus statement on the management of cardiac sarcoidosis from the ...

A breakthrough new AI model is able to detect the presence of different lung diseases from ultrasound videos, with 96.57% accuracy, and it is even able to distinguish whether the abnormalities are ...